A. Eggermont

发表

Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer

A. Y. de Kanter, C. V. van Eijck, A. V. van Geel, 1999, The British journal of surgery.

Rising trends in the incidence of and mortality from cutaneous melanoma in the Netherlands: a Northwest to Southeast gradient?

A. Eggermont, L. Schouten, O. Visser, 2003, European journal of cancer.

Public awareness about risk factors could pose problems for case-control studies: the example of sunbed use and cutaneous melanoma.

J. Coebergh, G. Severi, V. Bataille, 2005, European journal of cancer.

Abdominosacral resection for locally advanced and recurrent rectal cancer

A. Eggermont, J. D. Wilt, M. Vermaas, 2009, The British journal of surgery.

A. Paradiso, P. Johnston, A. Eggermont, 2022 .

Hyphenated techniques in anticancer drug monitoring. II. Liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry.

M. Highley, A. Eggermont, U. Tjaden, 2002, Journal of chromatography. A.

Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.

H. Hoekstra, A. V. van Geel, A. Eggermont, 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas.

H. Hoekstra, A. V. van Geel, A. Eggermont, 1998, Seminars in surgical oncology.

Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.

C. Seynaeve, A. Eggermont, J. Klijn, 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Transforming growth factor beta secretion from primary breast cancer fibroblasts

J. Foekens, J. Klijn, A. Eggermont, 1995, Molecular and Cellular Endocrinology.

Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.

A. Eggermont, C. Lamers, J. Gratama, 1995, Journal of the National Cancer Institute.

Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.

A. Lanzavecchia, A. Eggermont, C. Lamers, 1992, International journal of cancer. Supplement = Journal international du cancer. Supplement.

Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer.

J. Nuyttens, A. Eggermont, T. Wiggers, 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Total pelvic exenteration for primary locally advanced and recurrent rectal cancer

J. Nuyttens, A. Eggermont, T. Wiggers, 2004, Annals of Surgical Oncology.

Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population‐based series

A. Eggermont, J. Ijzermans, J. D. de Wilt, 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Total Pelvic Exenteration for Primary and Recurrent Malignancies

A. Eggermont, J. D. Wilt, J. D. de Wilt, 2009, World Journal of Surgery.

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

A. Eggermont, P. D. De Mulder, J. Gratama, 1996, British Journal of Cancer.

Interleukin-2

A. Eggermont, C. Lamers, G. Stoter, 1990 .

Monitoring stage-specific trends in melanoma incidence across Europe reveals the need for more complete information on diagnostic characteristics

F. Bray, A. Eggermont, E. de Vries, 2004, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Hyphenated techniques in anticancer drug monitoring. I. Capillary gas chromatography-mass spectrometry.

M. Highley, A. V. van Oosterom, A. Eggermont, 2002, Journal of chromatography. A.

Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

C. Punt, C. Scheibenbogen, A. Eggermont, 1997, The cancer journal from Scientific American.

Involvement of endothelial monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy.

A. Eggermont, A. Eggermont, T. Lans, 2004, Anticancer research.

Isolated limb perfusion in primary and recurrent melanoma: indications and results.

A. Eggermont, A. Eggermont, B. Kroon, 1998, Seminars in surgical oncology.

Rationale for using TNFα and chemotherapy in regional therapy of melanoma

A. Eggermont, A. Eggermont, P. Schmitz, 1994 .

Characteristics and uses of IL-2 in immunotherapy

A. Eggermont, G. Stoter, R. Bolhuis, 1989, Biotherapy.

Harly endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high‐dose tumour necrosis factor alpha (rTNFα)

A. Eggermont, A. Eggermont, R. Heimann, 1994 .

Should internal mammary chain (IMC) sentinel node biopsy be performed? Outcome in 90 consecutive non-biopsied patients with a positive IMC scintigraphy.

A. Y. de Kanter, A. V. van Geel, A. Eggermont, 2008, Breast.

Satisfaction and prosthesis related complaints in women with immediate breast reconstruction following prophylactic and oncological mastectomy

A. Eggermont, A. V. van Geel, C. Contant, 2004 .

Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results.

A. Eggermont, P. Schmitz, J. Gérain, 1995, The Journal of infusional chemotherapy.

Prolonged continuous hepatic artery infusion with interleukin-2 in unresectable liver metastases of colorectal cancer: a phase IA-B study.

A. Eggermont, T. Wiggers, G. Stoter, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical experience with the combined use of recombinant interleukin‐2 (IL2) and interferon alfa‐2a (IFNα) in metastatic melanoma

J. Monson, R. Stahel, A. Eggermont, 1991, British journal of haematology.

In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour

A. Eggermont, R. Marquet, A. Oosterom, 1993, Journal of Cancer Research and Clinical Oncology.

Lack of efficacy of Doxil® in TNF-α-based isolated limb perfusion in sarcoma-bearing rats

A. Eggermont, S. Hoving, T. T. ten Hagen, 2004, British Journal of Cancer.

Short Communication Lack of efficacy of Doxil s in TNF-a-based isolated limb perfusion in sarcoma-bearing rats

A. Eggermont, S. Hoving, G. Ambagtsheer, 2004 .

Sentinel node biopsy for clear cell sarcoma.

A. V. van Geel, A. Eggermont, C. Verhoef, 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat

A. Eggermont, R. Marquet, A. M. Jonker, 1994, Journal of Cancer Research and Clinical Oncology.

Radiation protection for the sentinel node procedure in breast cancer.

A. Y. de Kanter, A. Eggermont, T. Wiggers, 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.

A. Eggermont, P. Schmitz, B. Kroon, 1999, Melanoma research.

Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.

A. Eggermont, P. Autier, B. Kroon, 1994, Melanoma research.

A Prospective Study on Silicone Breast Implants and the Silicone-Related Symptom Complex

A. Eggermont, A. Swaak, A. Swaak, 2002, Clinical Rheumatology.

Isolated hepatic perfusion in the pig with TNF-OC with and without melphalan

A. Eggermont, T. Wiggers, C. Hack, 2017 .

Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.

I. B. Borel Rinkes, A. Eggermont, T. Wiggers, 1997, British Journal of Cancer.

Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study.

A. Eggermont, H. Hoekstra, A. Eggermont, 1999, Archives of surgery.

Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response.

A. Eggermont, P. Schmitz, G. Stoter, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer.

A. Eggermont, A. Eggermont, C. Lamers, 1997, Journal of immunotherapy.

Patients' perception of the cause of their melanoma differs from that of epidemiologists

A. Eggermont, A. Eggermont, P. Autier, 2002, The British journal of dermatology.

Characteristics of tumor infiltration by adoptively transferred and endogenous natural‐killer cells in a syngeneic rat model: Implications for the mechanism behind anti‐tumor responses

G. Fleuren, P. Kuppen, C. V. D. van de Velde, 1998, International journal of cancer.

Reconstruction of chest wall defects with homologous dura mater grafts

A. V. van Geel, A. Eggermont, T. Wiggers, 1989, The British journal of surgery.

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

A. Eggermont, N. Chaput, A. Eggermont, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Contralateral recurrence and prognostic factors in familial non‐BRCA1/2‐associated breast cancer

C. Seynaeve, M. Menke-Pluymers, A. Eggermont, 2006, The British journal of surgery.

In vivo model systems in P-glycoprotein-mediated multidrug resistance.

A. Eggermont, R. Marquet, G. Stoter, 1998, Critical reviews in clinical laboratory sciences.

Aggressive angiomyxoma: multimodality treatments can avoid mutilating surgery.

A. V. van Geel, A. Eggermont, C. Verhoef, 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity.

A. V. van Geel, A. Eggermont, M. Gutman, 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Management of psychiatric adverse events with immunotherapy with interferon-alfa

A. Eggermont, J. Cornelissen, A. V. Van Gool, 1999, Acta Neuropsychiatrica.

Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model

J. Schellens, A. Eggermont, W. Loos, 1996, Journal of Cancer Research and Clinical Oncology.

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

R. Dummer, M. Gore, A. Eggermont, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.

N. Chaput, A. Eggermont, P. Lepage, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis

S. Bonvalot, A. Eggermont, A. Gronchi, 2014, The British journal of surgery.

Long‐term outcome of isolated limb perfusion with tumour necrosis factor‐α for patients with melanoma in‐transit metastases

A. V. van Geel, A. Eggermont, C. Verhoef, 2011, The British journal of surgery.

Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance

R. Pieters, K. Sikora, W. Siegert, 1991, Journal of Cancer Research and Clinical Oncology.

Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases.

A. Eggermont, J. D. de Wilt, C. Verhoef, 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma

A. Eggermont, J. D. de Wilt, P. Schmitz, 2007, The British journal of surgery.

Development and validation of a nomogram to predict recurrence and melanoma‐specific mortality in patients with negative sentinel lymph nodes

D. van Klaveren, P. Rutkowski, A. Eggermont, 2018, The British journal of surgery.

TREATMENT OF SOFT TISSUE SARCOMA OF THE LIMB WITH LIPOSOME-ENCAPSULATED TUMOR NECROSIS FACTOR ?? IN THE RAT

A. Eggermont, T. Hagen, A. H. V. D. Veen, 1996 .

Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat

A. Eggermont, A. Eggermont, R. Marquet, 1996, The British journal of surgery.

Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients

A. Eggermont, A. V. van Geel, A. Eggermont, 2005, Journal of surgical oncology.

Systemic leakage during isolated limb perfusion for melanoma

A. Eggermont, J. Klaase, B. Kroon, 1993, The British journal of surgery.

Isolated limb perfusion for melanoma patients—a review of its indications and the role of tumour necrosis factor-α

A. Eggermont, D. Grünhagen, A. N. Geel, 2006 .

Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas

P. Wielopolski, A. Eggermont, G. Krestin, 2004, Magnetic Resonance Materials in Physics, Biology and Medicine.

Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.

A. Hart, A. V. van Geel, A. Eggermont, 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities.

A. Hart, A. V. van Geel, A. Eggermont, 1995, European journal of cancer.

Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma.

A. Eggermont, P. Schmitz, J. Gérain, 1994, Circulatory shock.

Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factor-alpha.

A. V. van Geel, A. Eggermont, J. D. de Wilt, 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Isolated Tumor Cells and Long-Term Prognosis of Patients with Melanoma

A. Eggermont, J. D. de Wilt, C. Verhoef, 2008, Annals of Surgical Oncology.

Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma

A. Testori, P. Rutkowski, A. Eggermont, 2017, The British journal of surgery.

Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans.

I. B. Borel Rinkes, R. Tollenaar, P. Kuppen, 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Determination of melphalan and hydrolysis products in body fluids by GC-MS

A. Eggermont, G. Boeck, K. V. Cauwenberghe, 1997 .

Administration of BiMAb‐Retargeted T Cells in a Rat Hepatic Metastases Colon Tumour Model Results in T‐Cell Tumour Infiltration Independent of the Route of Administration

G. Fleuren, A. Eggermont, R. Koelemij, 2001, Scandinavian journal of immunology.

9302 Excellent long-term survival of patients with minimal sentinel node tumor burden (<0.1 mm) according to Rotterdam Criteria: a study of the EORTC melanoma group

H. Hoekstra, P. Rutkowski, A. Eggermont, 2009 .

Long-term follow-up of patients with minimal sentinel node tumor burden (< 0.1mm) according to Rotterdam criteria: A study of the EORTC Melanoma Group.

I. V. D. van der Ploeg, H. Hoekstra, P. Rutkowski, 2009, Journal of Clinical Oncology.

Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands.

M. Janssen-Heijnen, S. Houterman, A. Eggermont, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognosis in patients with sentinel node‐positive melanoma without immediate completion lymph node dissection

A. Testori, P. Rutkowski, A. Eggermont, 2012, The British journal of surgery.

Influence of pegylated interferon-α therapy on plasma levels of citrulline and arginine in melanoma patients

S. Sleijfer, A. Eggermont, A. Eggermont, 2006, Amino Acids.

Results of regional isolated perfusion for locally inoperable melanoma of the limbs

A. Eggermont, J. Klaase, B B R Kroon, 1994, Melanoma research.

[Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience].

A. Eggermont, P. Schmitz, J. Gérain, 1995, Bulletin du Cancer.

Skin cancer incidence and survival in European children and adolescents (1978-1997). Report from the Automated Childhood Cancer Information System project.

E. Steliarova-Foucher, A. Eggermont, E. de Vries, 2006, European journal of cancer.

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.

N. Chaput, A. Eggermont, P. Lepage, 2019 .

[Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].

A. V. van Geel, A. Eggermont, J. D. de Wilt, 2005, Nederlands tijdschrift voor geneeskunde.

Intraperitoneal therapy of ovarian cancer with retargeted lymphocytes by bispecific monoclonal antibodies and interleukin-2

A. Eggermont, A. Eggermont, C. Lamers, 1995, Acta Chirurgica Austriaca.

Primary and secondary reconstruction after surgery of the irradiated pelvis using a gracilis muscle flap transposition.

A. Eggermont, C. Verhoef, J. D. de Wilt, 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Cutaneous Melanoma and Sentinel Lymph Node Biopsy

A. Eggermont, J. D. de Wilt, C. Verhoef, 2008, Annals of Surgical Oncology.

Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable sSewart-Treves lymphangiosarcoma.

A. V. van Geel, A. Eggermont, J. D. de Wilt, 2002, Annals of surgical oncology.

Reasons for failure to identify positive sentinel nodes in breast cancer patients with significant nodal involvement.

A. Y. de Kanter, C. V. van Eijck, A. V. van Geel, 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Role of ultrasound (US) and US-guided fine needle aspiration cytology (US-FNAC) prior to sentinel lymph node biopsy (SLNB) in 500 melanoma patients: Reduction of need for SNLB by high US-FNAC SN positive identification rate

A. Eggermont, W. Sterry, G. Schäfer-Hesterberg, 2007 .

Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.

I. B. Borel Rinkes, R. Tollenaar, P. Kuppen, 1999, European journal of clinical investigation.

Utility of repeat radiofrequency ablation to provide long-term local control in recurrent rectal cancer.

A. Eggermont, J. D. de Wilt, J. Kuiper, 2006, Surgery.

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

A. Eggermont, J. Gratama, G. Stoter, 1995, British Journal of Cancer.

Controlled introduction of the sentinel node biopsy in breast cancer in a multi-centre setting: the role of a coordinator for quality control.

E. Krenning, A. Y. de Kanter, C. V. van Eijck, 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Long-term follow-up of patients with minimal sentinel node tumor burden (<0.1mm) according to Rotterdam criteria

H. Hoekstra, P. Rutkowski, A. Eggermont, 2009 .

Isolated limb perfusion (ILP) with high dose TNF-α, gamma-IFN and melphalan in patients with irresectable soft tissue sarcomas: A highly effective limb saving procedure

H. Hoekstra, A. Eggermont, F. Lejeune, 1993 .

Subcutaneous tumor growth complicating the positioning of Denver shunt and intrapleural port-à-cath in mesothelioma patients.

A. Eggermont, T. Wiggers, B. van Ooijen, 1992, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients

J. Verweij, A. Eggermont, P. Schmitz, 1997, Cancer Immunology, Immunotherapy.

Sunscreen use and duration of sun exposure: a double-blind, randomized trial.

A. Eggermont, A. Eggermont, P. Autier, 1999, Journal of the National Cancer Institute.

Comparison of closed circuit and Fick‐derived oxygen consumption in patients undergoing simultaneous aortocaval occlusion

J. Hofland, D. Gommers, A. Eggermont, 2003, Anaesthesia.

Regulation of ferritin: a specific role for interferon‐alpha (IFN‐α)? The acute phase response in patients treated with IFN‐α‐2b

A. Eggermont, A. Swaak, T. Stam, 2002 .

‘Staged’ liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome

A. Eggermont, J. D. de Wilt, C. Verhoef, 2010, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Introduction of preoperative radiotherapy in the treatment of operable rectal cancer in the Southwest region of the Netherlands.

A. Eggermont, M. Vermaas, E. van der Harst, 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases

A. Eggermont, J. D. Wilt, C. Verhoef, 2010, The British journal of surgery.

5-Year follow-up of sentinel node negative breast cancer patients.

A. Y. de Kanter, A. V. van Geel, A. Eggermont, 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a

A. Eggermont, J. Thompson, A. Eggermont, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.

A. Eggermont, H. Hoekstra, A. V. van Geel, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions

A. Eggermont, J. D. de Wilt, A. Seynhaeve, 2000, British Journal of Cancer.

High tPA-expression in primary melanoma of the limb correlates with good prognosis

A. Eggermont, U. Kleeberg, H. Straatman, 2000, British Journal of Cancer.

Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.

J. Klijn, H. Meijers-Heijboer, C. Seynaeve, 2007, European journal of cancer.

Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer.

W. Hop, A. Eggermont, H. van Dekken, 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.

D. Schadendorf, A. Eggermont, D. Ruiter, 2004, European journal of cancer.

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

A. Eggermont, A. Eggermont, J. D. de Wilt, 2000, British Journal of Cancer.

TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects

A. Eggermont, A. Eggermont, J. D. de Wilt, 2000, British Journal of Cancer.

Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.

A. Eggermont, D. Ruiter, A. Eggermont, 1998, Cancer research.

Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-α-based isolated hepatic perfusion

A. Eggermont, A. Eggermont, T. Lans, 2003, British Journal of Cancer.

Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity

A. Eggermont, A. Eggermont, J. D. de Wilt, 2002, British Journal of Cancer.